Immix Biopharma (NASDAQ:IMMX) Stock Price Down 5.4% – What’s Next?

Posted by Stanley Muller on Sep 8th, 2026

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) fell 5.4% during mid-day trading on Tuesday . The stock traded as low as $12.75 and last traded at $13.16. 199,127 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 1,266,649 shares. The stock had previously closed at $13.91.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Bank of America assumed coverage on shares of Immix Biopharma in a research report on Thursday, June 18th. They set a “buy” rating and a $27.00 price target on the stock. Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a research note on Friday, August 14th. Lifesci Capital began coverage on shares of Immix Biopharma in a research report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Friday, July 17th. Finally, HC Wainwright upped their target price on Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Immix Biopharma presently has an average rating of “Moderate Buy” and an average price target of $21.29.

View Our Latest Analysis on IMMX

Immix Biopharma Trading Down 4.4%

The stock has a market capitalization of $951.48 million, a PE ratio of -15.15 and a beta of 0.20. The firm has a 50-day moving average price of $11.10 and a 200-day moving average price of $9.85.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Sell-side analysts expect that Immix Biopharma, Inc. will post -0.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC increased its stake in shares of Immix Biopharma by 9.5% during the 1st quarter. Private Advisor Group LLC now owns 34,725 shares of the company’s stock worth $316,000 after purchasing an additional 3,000 shares during the last quarter. Legal & General Group Plc purchased a new position in Immix Biopharma in the second quarter valued at approximately $41,000. Allworth Financial LP purchased a new position in Immix Biopharma in the fourth quarter valued at approximately $30,000. California State Teachers Retirement System bought a new position in Immix Biopharma during the second quarter valued at $566,000. Finally, Compass Financial Management LLC bought a new position in Immix Biopharma during the second quarter valued at $56,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.